| Bioactivity | CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 (KD=16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases[1]. |
| CAS | 2366279-86-7 |
| Sequence | {Dcn}-{Tle}-Ile-{Hva}-Ile-Thr-Gln-His-{d-Leu}-Ser-{miniPEG}-Lys-{CPP9} |
| Shortening | {Dcn}-{Tle}-I-{Hva}-ITQH-{d-Leu}-S-{miniPEG}-K-{CPP9} |
| Formula | C116H180Cl2N36O26 |
| Molar Mass | 2565.80 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dougherty PG, et al. A Peptidyl Inhibitor that Blocks Calcineurin-NFAT Interaction and Prevents Acute Lung Injury. J Med Chem. 2020 Nov 12;63(21):12853-12872. |
CNI103
CAS: 2366279-86-7 F: C116H180Cl2N36O26 W: 2565.80
CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively b
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.